Lilly Asia Ventures Receives $40M Commitment From US Pension Fund SFERS

Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has received a commitment of US$40 million for its fifth biosciences fund, LAV Biosciences Fund V, from U.S. public pension San Francisco City & County Employees’ Retirement System (SFERS).

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

LEAVE A REPLY